{
    "clinical_study": {
        "@rank": "126091", 
        "arm_group": [
            {
                "arm_group_label": "Nemonoxacin 500 mg", 
                "arm_group_type": "Experimental", 
                "description": "Nemonoxacin 500mg/250mL."
            }, 
            {
                "arm_group_label": "Nemonoxacin 650 mg", 
                "arm_group_type": "Experimental", 
                "description": "Nemonoxacin 650 mg/325mL"
            }, 
            {
                "arm_group_label": "Moxifloxacin 400 mg", 
                "arm_group_type": "Active Comparator", 
                "description": "Moxifloxacin 400mg/250mL"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to Evaluate the Efficacy, safety and pharmacokinetics of\n      Intravenous Nemonoxacin Compared with Intravenous Moxifloxacin in Adult Patients with\n      community-acquired pneumonia (CAP)."
        }, 
        "brief_title": "Study to Evaluate the Efficacy and Safety of Intravenous Infusion With TG-873870", 
        "condition": "Pneumonia", 
        "condition_browse": {
            "mesh_term": "Pneumonia"
        }, 
        "detailed_description": {
            "textblock": "Community-acquired Pneumonia (CAP) remains a leading cause of death in both developing and\n      developed countries. In the choice of antibacterial agents used to treat CAP,\n      fluoroquinolones have received considerable attention because of their wide spectrum of\n      bactericidal activity. TG-873870 (Nemonoxacin), a non-fluorinated quinolone (NFQ), is a\n      selective bacterial topoisomerase inhibitor.\n\n      This study will Evaluate the clinical efficacy, microbiological efficacy and safety of\n      Intravenous Nemonoxacin compared with Intravenous Moxifloxacin in adult patients with\n      community-acquired pneumonia.\n\n      Besides, the pharmacokinetics (PK) of Nemonoxacin in adult patients with CAP after\n      continuous IV Infusion and the pharmacokinetic (PK)/pharmacodynamic (PD)are to be\n      determined."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Ages between 18 and 75;\n\n          2. Weighs between 40 ~ 100 kg, and BMI \u2265 18 kg/m2;\n\n          3. Must have a clinical diagnosis of CAP\n\n          4. Chest X-ray and /or CT scan show new or persist/progressive infiltrates\n\n          5. Patients with PORT/PSI score II, III or IV.\n\n          6. If female, non-lactating and at no risk or pregnancy (post-menopausal or must use\n             adequate birth control)\n\n          7. The patient is able to receive an intravenous infusion of the drug .\n\n        Exclusion Criteria:\n\n          1. Patients with PORT/PSI score I or VI.\n\n          2. Severe CAP is present if a patient needs invasive mechanical ventilation or requires\n             vasopressors.\n\n          3. Known or suspected severe bronchiectasis, cystic fibrosis, active pulmonary\n             tuberculosis or infection with other mycobacteria or fungi, known bronchial\n             obstruction, a history of post-obstructive pneumonia, other confounding respiratory\n             diseases, such as lung cancer, malignancy metastatic to the lungs, lung abscess,\n             empyema, suspected aspiration pneumonia due to vomiting, or non-bacterial respiratory\n             infection (chronic obstructive pulmonary disease [COPD] is not exclusionary)\n\n          4. Clinically significant conduction or other abnormality on 12-lead ECG, or QTc\n             interval\n\n          5. Potassium is < 3.5 mmol/L\n\n          6. Any known disease that seriously affect the immune system\n\n          7. Active hepatitis or decompensated cirrhosis;\n\n          8. Have used quinolones or fluoroquinolones within 14 days before enrollment\n\n          9. Patients who are being or will be on a long-term medication of steroids"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "210", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 26, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01944774", 
            "org_study_id": "TG-873870-C-5"
        }, 
        "intervention": [
            {
                "arm_group_label": "Nemonoxacin 500 mg", 
                "description": "IV Infusion, once daily for 7~14 days", 
                "intervention_name": "Nemonoxacin 500 mg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Nemonoxacin 650 mg", 
                "description": "IV Infusion, once daily for 7~14 days", 
                "intervention_name": "Nemonoxacin 650 mg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Moxifloxacin 400 mg", 
                "description": "IV Infusion, once daily for 7~14 days", 
                "intervention_name": "Moxifloxacin 400 mg", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Moxifloxacin", 
                "Norgestimate, ethinyl estradiol drug combination"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "Moxifloxacin", 
        "lastchanged_date": "September 13, 2013", 
        "location": [
            {
                "contact": {
                    "email": "yyzhang@hsh.stn.sh.cn", 
                    "last_name": "Yingyuan Zhang, PhD"
                }, 
                "facility": {
                    "address": {
                        "city": "Shanghai", 
                        "country": "China", 
                        "zip": "200040"
                    }, 
                    "name": "Institute of Antibiotics, Huashan Hospital, Fundan University"
                }, 
                "investigator": {
                    "last_name": "Yingyuan Zhang, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "chest5415@hotmail.com", 
                    "last_name": "Shih-Lung Cheng"
                }, 
                "facility": {
                    "address": {
                        "city": "Taipei", 
                        "country": "Taiwan"
                    }, 
                    "name": "Far eastern memorial hospital"
                }, 
                "investigator": {
                    "last_name": "Shih-Lung Cheng", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "China", 
                "Taiwan"
            ]
        }, 
        "number_of_arms": "3", 
        "official_title": "A Multi-Center, Randomized, Double-Blind, Parallel Comparative, Phase II Study to Evaluate the Efficacy and Safety of Intravenous Infusion With Nemonoxacin Versus Moxifloxacin in Treating Adult Patients With CAP", 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "November 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Per subject clinical cure rate", 
            "safety_issue": "Yes", 
            "time_frame": "14~28 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01944774"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Number of Participants with Adverse Events as a Measure of Safety and Tolerability", 
                "safety_issue": "Yes", 
                "time_frame": "28 days"
            }, 
            {
                "measure": "Per subject microbiological cure rate", 
                "safety_issue": "Yes", 
                "time_frame": "14~28 days"
            }, 
            {
                "measure": "Per subject overall cure rate", 
                "safety_issue": "Yes", 
                "time_frame": "14~28 days"
            }
        ], 
        "source": "TaiGen Biotechnology Co., Ltd.", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "QPS-Qualitix", 
                    "agency_class": "Industry"
                }, 
                {
                    "agency": "R&G Pharma Studies Co.,Ltd.", 
                    "agency_class": "Industry"
                }
            ], 
            "lead_sponsor": {
                "agency": "TaiGen Biotechnology Co., Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "September 2013"
    }
}